MVZ München Am Goetheplatz, Waltherstr. 32, 80337, Munich, Germany.
MUC Research, Munich, Germany.
Infection. 2022 Jun;50(3):617-623. doi: 10.1007/s15010-021-01721-7. Epub 2021 Oct 25.
To describe the humoral immune response to COVID-19 vaccines in people living with HIV and identify factors associated with the magnitude of anti-SARS-CoV-2 antibody concentrations.
Retrospective analysis of electronic patient files in a big single HIV center in Munich, Germany. Non-parametric methods were used for descriptive and comparative statistics. Generalized linear models were used to analyze associations of general and HIV-specific variables with anti-SARS-CoV-2 antibody concentrations after standard vaccination.
Overall, 665 people living with HIV were included into the analysis (median age: 53 [IQR: 43; 59]), 560 [84.2%] males). Median concentration of anti-SARS-CoV-2-antibodies was 1400 (IQR 664; 2130) BAU/mL. In 18 (2.7%) subjects, antibody concentrations below the threshold of 34 BAU/mL were found. Among PLWH with CD4 cell count < 200 cells/µL, median anti-SARS-CoV-2-Abs were 197 (IQR 44.6; 537.2) as compared to 1420 (IQR 687; 2216) for the group ≥ 200 cells/µL (p < 0.001). In a cumulative logit model, a vaccination scheme including an mRNA vaccine [OR: 4.64 (3.58; 6.02)], being female [OR: 2.14 (1.76; 2.61)], and having higher CD4 cells [OR per 100 cells/µL: 1.06 (1.04; 1.08)] were significantly associated with anti-SARS-CoV-2 antibody concentrations in higher quartiles, when adjusted for the time after vaccination.
We found a robust antibody response in people living with HIV undergoing standard vaccination against SARS-CoV-2. mRNA-containing vaccination schemes, being female, and having a higher CD4 cell count was associated with a higher concentration of antibodies in people living with HIV in our study sample. Particularly in the subgroup with CD4 cell counts < 200 cells/µL, antibody response was poor.
描述感染人类免疫缺陷病毒（HIV）人群对 COVID-19 疫苗的体液免疫反应，并确定与 SARS-CoV-2 抗体浓度大小相关的因素。
对德国慕尼黑一家大型单一 HIV 中心的电子病历进行回顾性分析。使用非参数方法进行描述性和比较性统计。使用广义线性模型分析一般和 HIV 特异性变量与标准接种后 SARS-CoV-2 抗体浓度的关联。
共纳入 665 名 HIV 感染者（中位年龄：53 [IQR：43；59]，560 名[84.2%]男性）。SARS-CoV-2 抗体浓度中位数为 1400（IQR 664；2130）BAU/mL。18 名（2.7%）患者抗体浓度低于 34 BAU/mL。在 CD4 细胞计数 < 200 个/μL 的 PLWH 中，SARS-CoV-2-Abs 中位数为 197（IQR 44.6；537.2），而 CD4 细胞计数 ≥ 200 个/μL 的组为 1420（IQR 687；2216）（p < 0.001）。在累积对数模型中，包含 mRNA 疫苗的疫苗接种方案[比值比：4.64（3.58；6.02）]、女性[比值比：2.14（1.76；2.61）]和更高的 CD4 细胞数[每 100 个细胞/μL 的比值比：1.06（1.04；1.08）]与调整接种后时间后的 SARS-CoV-2 抗体浓度较高四分位数显著相关。
我们发现，在接受 SARS-CoV-2 标准疫苗接种的 HIV 感染者中，抗体反应强劲。在我们的研究样本中，包含 mRNA 的疫苗接种方案、女性和更高的 CD4 细胞计数与 HIV 感染者的抗体浓度较高相关。特别是在 CD4 细胞计数 < 200 个/μL 的亚组中，抗体反应较差。
